Cassava Sciences 将来の成長

NasdaqCM:SAVA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	5	N/A	N/A	1
12/31/2025	N/A	-21	N/A	N/A	2
12/31/2024	N/A	-29	N/A	N/A	2
9/30/2024	N/A	-18	-78	-78	N/A
6/30/2024	N/A	-15	-86	-86	N/A
3/31/2024	N/A	-48	-88	-88	N/A
12/31/2023	N/A	-97	-82	-82	N/A
9/30/2023	N/A	-95	-81	-81	N/A
6/30/2023	N/A	-90	-77	-76	N/A
3/31/2023	N/A	-83	-70	-67	N/A
12/31/2022	N/A	-76	-80	-78	N/A
9/30/2022	N/A	-71	-67	-64	N/A
6/30/2022	N/A	-61	-81	-57	N/A
3/31/2022	N/A	-46	-74	-51	N/A
12/31/2021	N/A	-32	-52	-30	N/A
9/30/2021	N/A	-21	-45	-23	N/A
6/30/2021	N/A	-13	-11	-11	N/A
3/31/2021	N/A	-9	-6	-6	N/A
12/31/2020	N/A	-6	-5	-5	N/A
9/30/2020	N/A	-5	-5	-5	N/A
6/30/2020	N/A	-4	-3	-3	N/A
3/31/2020	N/A	-4	-3	-3	N/A
12/31/2019	N/A	-5	-3	-3	N/A
9/30/2019	N/A	-4	-3	-2	N/A
6/30/2019	N/A	-4	-3	-3	N/A
3/31/2019	N/A	-6	-4	-4	N/A
12/31/2018	N/A	-7	-5	-5	N/A
9/30/2018	N/A	-8	-6	-6	N/A
6/30/2018	N/A	-10	N/A	-6	N/A
3/31/2018	N/A	-11	N/A	-8	N/A
12/31/2017	N/A	-12	N/A	-8	N/A
9/30/2017	N/A	-12	N/A	-10	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-12	N/A	-11	N/A
12/31/2016	N/A	-15	N/A	-12	N/A
9/30/2016	N/A	-17	N/A	-13	N/A
6/30/2016	N/A	-17	N/A	-12	N/A
3/31/2016	N/A	-17	N/A	-11	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A
6/30/2015	N/A	-12	N/A	-7	N/A
3/31/2015	N/A	-12	N/A	-8	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
9/30/2014	35	23	N/A	-8	N/A
6/30/2014	37	26	N/A	-9	N/A
3/31/2014	39	29	N/A	-8	N/A
12/31/2013	41	32	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SAVAは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: SAVA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: SAVA今後 3 年以内に収益を上げることが予想されます。

収益対市場: SAVAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: SAVA来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SAVAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cassava Sciences 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$0.77 loss

Forecast to breakeven in 2023

Price target increased to US$84.00

Price target decreased to US$58.67

Forecast to breakeven in 2022

Recent updates

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Cassava Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

New minor risk - Profitability

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Expansion of Open-Label Extension Trials

Cassava Sciences: Turning The Corner Into A Brick Wall

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

New minor risk - Profitability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Independent Director exercised options to buy US$3.9m worth of stock.

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia

Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index

Cassava Sciences, Inc. Announces Board Appointments

New major risk - Revenue and earnings growth

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease

Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease

Independent Director recently bought US$308k worth of stock

New major risk - Revenue and earnings growth

Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging

Founder exercised options and sold US$480k worth of stock

Lead Independent Director exercised options to buy US$259k worth of stock.

Independent Director recently bought US$2.3m worth of stock

Consensus EPS estimates upgraded to US$0.77 loss

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Forecast to breakeven in 2023

Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Price target increased to US$84.00

Cassava Sciences, Inc. Announces Executive Changes

Cassava Sciences, Inc. Announces Completion of Dosing in Open-Label Study of Simufilam for Alzheimer’s Disease

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences, Inc. Appoints Christopher Cook as Senior Vice President and General Counsel

Cassava Sciences Announces Initiation of an Open-Label Extension Study

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Cassava Sciences: Trying To Manage Expectations

Lead Independent Director exercised options to buy US$86k worth of stock.

Cassava Sciences reaches over five-month high on rising volumes

Cassava Sciences Looks As Good Of A Purchase As Ever

Cassava Sciences stock jumps 10% after director buys $860K shares

Chief Clinical Development Officer recently bought US$61k worth of stock

Lead Independent Director recently bought US$2.1m worth of stock

Cassava Sciences rally continues as stock up 39%

Price target decreased to US$58.67

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Founder exercised options and sold US$249k worth of stock

Chief Medical Officer & Director exercised options and sold US$81k worth of stock

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

Founder exercised options to buy US$1.0m worth of stock.

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences